Experienced in Lichen Planus

Jin U. Li

Union Hospital, 
Wuhan, CN 
Experienced in Lichen Planus
Union Hospital, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Jin Li practices in Wuhan, China. Li is rated as an Experienced expert by MediFind in the treatment of Lichen Planus. Their top areas of expertise are Stomach Cancer, Colorectal Cancer, Learman Syndrome, Hysterectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 405 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Lichen Planus.

Locations

Union Hospital, Wuhan, 430022, China
Other Locations
No. 1095, Jiefang Avenue, Wuhan, 430030, China
No.1095 Jiefang Avenue, Wuhan, 430030, China
No. 150 Jimo Road, Pudong, 200120, China
No.639, Zhizaoju Road, Huangpu, 200011, China
No. 1800 Yuntai Road, Pudong, China
60 Longmen Street, Suizhou, 441300, China
Pr, Wuhan, China
270 Dong An Road, Shanghai, 200032, China
No. 13 Hangkong Road, Wuhan, 430030, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Drug
Study Drug: SKB264
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ia, Multicenter, Open-label Study of ILB2109 in Patients With Advanced Solid Malignancies
A Phase Ia, Multicenter, Open-label Study of ILB2109 in Patients With Advanced Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characters, and Preliminary Efficacy of SCC244 in Patients with Advanced MET Alterations Solid Tumors
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characters, and Preliminary Efficacy of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Sitravatinib, Tislelizumab
Study Phase: Phase 1/Phase 2
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2024
Intervention Type: Drug
Study Drug: HH2710
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
Enrollment Status: Completed
Publish Date: November 09, 2023
Intervention Type: Dietary supplement, Drug
Study Drug: JMT103
Study Phase: Phase 1
A Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
A Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Enrollment Status: Unknown
Publish Date: July 19, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors.
An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: April 12, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Study of CM082 Tablets in the Treatment of Advanced Malignant Solid Tumors: Safety, Tolerance and Pharmacokinetics
Phase I Study of CM082 Tablets in the Treatment of Advanced Malignant Solid Tumors: Safety, Tolerance and Pharmacokinetics
Enrollment Status: Unknown
Publish Date: November 14, 2022
Intervention Type: Drug
Study Phase: Phase 1
Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study
Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Phase: Phase 4
View 10 Less Clinical Trials

405 Total Publications

Diagnostic Potential of Circulating lncRNA SNHG5 in Osteoporotic Fractures and Its Mechanistic Role in Accelerating Fracture Healing.
Diagnostic Potential of Circulating lncRNA SNHG5 in Osteoporotic Fractures and Its Mechanistic Role in Accelerating Fracture Healing.
Journal: Journal of investigative surgery : the official journal of the Academy of Surgical Research
Published: November 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 78 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile